Bio News
U.S.-based Electra Therapeutics raised $350 million through an initial public offering (IPO) on Nasdaq.
Electra Therapeutics sold 23.3 million shares at $15 per share, more than initially expected.
Electra Therapeutics will use the funds to advance Phase 2/3 clinical trials and seek regulatory approval for its immune cell-targeting drug, isofprovat.
BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery
